HALF, NCT04147533: Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia |
|
|
| Active, not recruiting | 2 | 150 | RoW | Imatinib withdrawal, Glivec withdrawal, Dasatinib, Sprycel withdrawal, Nilotinib, Tasigna withdrawal | Masaryk University | Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug | 06/26 | 06/26 | | |